Effects of canagliflozin, an SGLT2 inhibitor, on hepatic function in Japanese patients with type 2 diabetes mellitus: pooled and subgroup analyses of clinical trials.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Works matching DE "SODIUM metabolism inhibitors"
Results: 13
1
2
Effect of Food on the Pharmacokinetics of Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, and Assessment of Dose Proportionality in Healthy Participants.
- Published in:
- Clinical Pharmacology in Drug Development, 2015, v. 4, n. 4, p. 279, doi. 10.1002/cpdd.151
- By:
- Publication type:
- Article
3
Sglt2 Inhibitors - Is the Paradigm in Type 2 Diabetes Mellitus Management Changing ?
- Published in:
- Romanian Journal of Diabetes Nutrition & Metabolic Diseases, 2014, v. 21, n. 4, p. 261, doi. 10.2478/rjdnmd-2014-0031
- By:
- Publication type:
- Article
4
Efficacy of canagliflozin combined with antidiabetic drugs in treating type 2 diabetes mellitus: Meta-analysis of randomized control trials.
- Published in:
- Journal of Diabetes Investigation, 2016, v. 7, n. 3, p. 359, doi. 10.1111/jdi.12417
- By:
- Publication type:
- Article
5
Longer-term safety and tolerability of canagliflozin in patients with type 2 diabetes: a pooled analysis.
- Published in:
- 2017
- By:
- Publication type:
- journal article
6
Role of Tartaric Acid in Chemical, Mechanical and Self-Healing Behaviors of a Calcium-Aluminate Cement Blend with Fly Ash F under Steam and Alkali Carbonate Environments at 270 °C.
- Published in:
- Materials (1996-1944), 2017, v. 10, n. 4, p. 342, doi. 10.3390/ma10040342
- By:
- Publication type:
- Article
7
Effects of Canagliflozin on Serum Magnesium in Patients With Type 2 Diabetes Mellitus: A Post Hoc Analysis of Randomized Controlled Trials.
- Published in:
- 2017
- By:
- Publication type:
- Report
8
Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors.
- Published in:
- 2015
- By:
- Publication type:
- Opinion
9
Bone effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus.
- Published in:
- 2017
- By:
- Publication type:
- journal article
10
An evidence-based practice-oriented review focusing on canagliflozin in the management of type 2 diabetes.
- Published in:
- 2017
- By:
- Publication type:
- journal article
11
Canagliflozin attenuates the progression of atherosclerosis and inflammation process in APOE knockout mice.
- Published in:
- Cardiovascular Diabetology, 2018, v. 17, n. 1, p. N.PAG, doi. 10.1186/s12933-018-0749-1
- By:
- Publication type:
- Article
12
Fixed-dose combinations in type 2 diabetes - role of the canagliflozin metformin combination.
- Published in:
- Diabetes, Metabolic Syndrome & Obesity: Targets & Therapy, 2015, v. 8, p. 287, doi. 10.2147/DMSO.S69282
- By:
- Publication type:
- Article
13
Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2016, v. 18, n. 1, p. 82, doi. 10.1111/dom.12589
- By:
- Publication type:
- Article